Moexipril Hydrochloride and Hydrochlorothiazide (Glenmark Pharmaceuticals Inc., USA)
Welcome to the PulseAid listing for the Moexipril Hydrochloride and Hydrochlorothiazide drug offered from Glenmark Pharmaceuticals Inc., USA. This Angiotensin Converting Enzyme Inhibitor [EPC],Angiotensin-converting Enzyme Inhibitors [MoA],Increased Diuresis [PE],Thiazide Diuretic [EPC],Thiazides [Chemical/Ingredient] pharmaceutical is classified as a HUMAN PRESCRIPTION DRUG. Below, you can view details for this drug, such as its dosage form, route of delivery, start market/end market dates, and more. We have also randomly listed additional pharmaceuticals used in the same HUMAN PRESCRIPTION DRUG drug type category.
LABELER NAME / MANUFACTURER: | Glenmark Pharmaceuticals Inc., USA |
NON-PROPRIETARY NAME: | Moexipril Hydrochloride and Hydrochlorothiazide |
SUBSTANCE NAME: | MOEXIPRIL HYDROCHLORIDE; HYDROCHLOROTHIAZIDE |
TYPE: | HUMAN PRESCRIPTION DRUG |
PHARMA CLASS: | Angiotensin Converting Enzyme Inhibitor [EPC],Angiotensin-converting Enzyme Inhibitors [MoA],Increased Diuresis [PE],Thiazide Diuretic [EPC],Thiazides [Chemical/Ingredient] |
ROUTE: | ORAL |
DOSAGE FORM: | TABLET, FILM COATED |
MARKETING CATEGORY NAME: | ANDA |
START MARKETING DATE: | 2010-03-18 |
END MARKETING DATE: | 0000-00-00 |
Moexipril Hydrochloride and Hydrochlorothiazide HUMAN PRESCRIPTION DRUG Details:
Item Description | Moexipril Hydrochloride and Hydrochlorothiazide from Glenmark Pharmaceuticals Inc., USA |
LABELER NAME: | Glenmark Pharmaceuticals Inc., USA |
DEA SCHEDULE: |
|
ACTIVE STRENGTH: | 15; 25(mg/1; mg/1) |
START MARKETING DATE: | 2010-03-18 |
END MARKETING DATE: | 0000-00-00 |
PRODUCT ID: | 68462-205_cc336802-c12f-4880-950f-e306340578d5 |
PRODUCT NDC: | 68462-205 |
APPLICATION NUMBER: | ANDA090718 |
Other MOEXIPRIL HYDROCHLORIDE; HYDROCHLOROTHIAZIDE Pharmaceutical Manufacturers / Labelers: